Hemodynamic Effects of Ibopamine on the Pulmonary Circulation and Right Ventricular Performance in Patients with Chronic Obstructive Pulmonary Disease

Abstract

We have studied the effects of ibopamine, an oral dopamine derivative, on pulmonary hemodynamics and blood gas values when given as a single oral dose (100 mg) to patients with severe hypoxic chronic obstructive pulmonary disease. A small but significant increase in mean pulmonary arterial pressure from 29 ± 8 to 32 ± 7 mm Hg (p < 0.01) was noted 30min after ibopamine was given associated with a small increase in cardiac index. No other consistent hemodynamic changes were observed, and no alteration in blood gas values or oxygen saturation occurred. These results do not indicate a role for ibopamine in the treatment of patients with hypoxic chronic obstructive pulmonary disease and pulmonary hypertension, but, in addition, do not indicate any major deleterious effects of ibopamine on pulmonary hemodynamics or blood gas values in such patients.

Ibopamine

“…This change then reversed and significant decreases in both to-561 tal pulmonary and systemic vascular resistances were noted at 60 minutes postdose (table I), coinciding with the peak increase in cardiac output. A single dose of ibopamine 100mg had no deleterious effect on pulmonary haemodynamics or blood gas values in 8 patients with hypoxic chronic obstructive pulmonary disease and pulmonary hypertension, producing minimal change in mean pulmonary artery pressure (from 29 to 32mm Hg) [Skwarski et al 1992]. However, a causal relationship between increased pulmonary capillary wedge pressure and dyspnoea is controversial (Marchionni et al 1986).…”